Newron Pharmaceuticals S.p.A.
Biopharmaceutical company developing therapies for nervous system disorders and pain.
NWRN | SW
Overview
Corporate Details
- ISIN(s):
- IT0004147952
- LEI:
- 8156002F8C11F80A9740
- Country:
- Italy
- Address:
- VIA MEUCCI, 3, 20091 BRESSO
- Website:
- https://www.newron.com/
- Sector:
- Manufacturing
Description
Newron Pharmaceuticals is a biopharmaceutical company focused on the research and development of novel therapies for diseases of the central and peripheral nervous system (CNS) and pain. The company's portfolio includes Xadago® (safinamide), a globally partnered treatment for Parkinson's disease. Its clinical-stage pipeline is centered on CNS disorders, with a key candidate, evenamide, under investigation for the treatment of schizophrenia.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-01-09 07:00 |
Newron and Myung In Pharm announce license agreement for evenamide in South Kor…
|
English | 20.8 KB | ||
| 2025-01-09 01:00 |
EQS-News: Newron and Myung In Pharm announce license agreement for evenamide in…
|
English | 16.9 KB | ||
| 2025-01-09 01:00 |
EQS-News: Newron und Myung In Pharm geben Lizenzvereinbarung für Evenamide in S…
|
German | 19.1 KB | ||
| 2024-12-13 01:00 |
EQS-Adhoc: Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben…
|
German | 16.2 KB | ||
| 2024-12-13 01:00 |
EQS-News: Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce licen…
|
English | 19.1 KB | ||
| 2024-12-13 01:00 |
EQS-News: Newron und EA Pharma (Tochtergesellschaft von Eisai Co., Ltd.) geben …
|
German | 22.0 KB | ||
| 2024-09-19 02:00 |
EQS-Adhoc: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und …
|
German | 21.0 KB | ||
| 2024-09-19 02:00 |
EQS-News: Newron presents H1 2024 results and provides business update
|
English | 25.5 KB | ||
| 2024-09-19 02:00 |
EQS-News: Newron veröffentlicht die Ergebnisse des ersten Halbjahres 2024 und g…
|
German | 29.3 KB | ||
| 2024-06-25 02:00 |
EQS-News: Newron Pharmaceuticals reports on its 2024 Investor Day in New York C…
|
English | 17.9 KB | ||
| 2024-06-25 02:00 |
EQS-News: Newron Pharmaceuticals berichtet vom Investorentag 2024 in New York C…
|
German | 19.9 KB | ||
| 2024-06-18 02:00 |
EQS-News: Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New Yor…
|
English | 15.0 KB | ||
| 2024-06-18 02:00 |
EQS-News: Investorentag 2024 von Newron Pharmaceuticals am 25. Juni 2025 in New…
|
German | 15.7 KB | ||
| 2024-06-05 02:00 |
EQS-News: Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in…
|
English | 14.7 KB | ||
| 2024-06-05 02:00 |
EQS-News: Newron Pharmaceuticals lädt zum Investorentag 2024 am 25. Juni in New…
|
German | 15.6 KB |
Automate Your Workflow. Get a real-time feed of all Newron Pharmaceuticals S.p.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Newron Pharmaceuticals S.p.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Newron Pharmaceuticals S.p.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
